Last reviewed · How we verify
NCT06860620
Efficacy of Zinc Supplementation in Maintaining Sustained Remission in Children With Steroid-sensitive Nephrotic Syndrome
NA trial testing Zinc supplementation plus standard treatment in Steroid-Sensitive Nephrotic Syndrome in 192 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Muhammad Aamir Latif |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 192 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Zinc supplementation plus standard treatment — full drug profile →
Conditions studied
- Steroid-Sensitive Nephrotic Syndrome — all drugs for Steroid-Sensitive Nephrotic Syndrome →
Sponsor
Muhammad Aamir Latif — full company profile →
Who can join
Adults 2 to 12, any sex, with Steroid-Sensitive Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to fill the gaps by determining the efficacy of zinc supplementation in maintaining sustained remission in children with steroid sensitive nephrotic syndrome (SSNS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06860620
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Steroid-Sensitive Nephrotic Syndrome
Currently open trials in the same condition.
- NCT05786768 — Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syn · Phase 2, PHASE3 · recruiting
- NCT06065852 — National Registry of Rare Kidney Diseases · recruiting
Other Muhammad Aamir Latif trials
Trials by the same sponsor.
- NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
- NCT07426744 — Antipyretic Therapy With and Without Cold Sponging · NA · not yet recruiting
- NCT07437391 — Effect of L-Carnitine Supplementation in Preterm Neonates · NA · recruiting
- NCT07313670 — Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock · NA · not yet recruiting
- NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06860620 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muhammad Aamir Latif
- Last refreshed: 6 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860620.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing